Skip to main content
. Author manuscript; available in PMC: 2017 Dec 15.
Published in final edited form as: Clin Cancer Res. 2016 Jun 24;22(24):6129–6141. doi: 10.1158/1078-0432.CCR-16-0326

Figure 3.

Figure 3

Active exposures of rapamycin are achievable in vivo at low doses.

A) Immunoblot for phospho- and total p70S6K in K7M2 (murine) and MG63.3 (human) highly metastatic osteosarcoma cells treated with vehicle, 0.1μM rapamycin, or 1μM rapamycin for 4 hours. Images cropped to show relevant bands.

B) Whole blood rapamycin levels on day 14 in mice receiving 5mg/kg IP rapamycin three times per week. Blood was drawn on day 14 prior to treatment (trough) as well as 2 and 6 hours following IP administration of 5mg/kg rapamycin. N=3 mice.

C) Whole blood rapamycin levels in naïve mice treated with a single dose of 5mg/kg rapamycin IP. Whole blood was collected immediately following rapamycin administration (0 hours) and at 2, 6, 24, and 48 hour time points. N=3 mice.